Intrinsic ALK-TKI Resistance Due to MetCoamplification in ALK plus NSCLC, Effectively Treated by Alectinib-crizotinib Combination

被引：0
|
作者：
Urbanska, E. M. [1 ]
Melchior, L. C. [1 ]
Sorensen, J. B. [1 ,2 ]
Santoni-Rugiu, E. [1 ,2 ]
机构：
[1] Rigshosp, Copenhagen Univ Hosp, Copenhagen, Denmark
[2] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
de novo MET-amplification; intrinsic ALK-TKI resistance; TKIs combination;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP.12B.12
引用
收藏
页码：S645 / S646
页数：2
相关论文
共 50 条
  • [21] Pooled Analysis of CNS Response to Alectinib in Two Studies of Pre-Treated ALK plus NSCLC
    Gadgeel, Shirish
    Shaw, A.
    Govindan, Ramaswamy
    Socinski, Mark A.
    Camidge, Ross
    De Petris, Luigi
    Kim, Dong-Wan
    Chiappori, Alberto
    Moro-Sibilot, Denis
    Duruisseaux, Michael
    Crino, Lucio
    De Pas, Tommaso
    Dansin, Eric
    Tessmer, Antje
    Yang, James Chih-Hsin
    Ji-Youn, Han
    Bordogna, Walter
    Golding, Sophie
    Zeaiter, Ali
    Ou, Ignatius
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S238 - S238
  • [22] Sustained Response to Crizotinib After Resistance to First-Line Alectinib Treatment in Two Patients With ALK-Rearranged NSCLC
    Zheng, Jing
    Sun, Wenjia
    Chen, Wenhong
    Zhou, Jianying
    Zhou, Jianya
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (09) : E150 - E153
  • [23] ALTA-3: A randomized trial of brigatinib (BRG) vs alectinib (ALC) in crizotinib (CRZ)-refractory advanced ALK plus NSCLC
    Yang, J. C-H.
    Liu, G.
    Lu, S.
    He, J.
    Burotto, M.
    Vincent, S.
    Yin, J.
    Ma, X.
    Popat, S.
    ANNALS OF ONCOLOGY, 2022, 33 : S1564 - S1564
  • [24] Update of the INSPIRE study: Iruplinalkib versus crizotinib in ALK TKI-naive locally advanced or metastatic ALK plus non-small cell lung cancer (NSCLC)
    Shi, Y-K.
    Chen, J.
    Yang, R.
    Wu, H.
    Wang, Z.
    Yang, W.
    Cui, J.
    Zhang, Y.
    Liu, C.
    Cheng, Y.
    Liu, Y.
    Shan, J.
    Wang, D.
    Yang, L.
    Hu, C.
    Si, M.
    Li, H.
    Li, L.
    Kang, X.
    Wang, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S815 - S815
  • [25] Updated efficacy and safety of the j-alex study comparing alectinib (ALC) with crizotinib (CRZ) in ALK-inhibitor naive ALK fusion positive non-small cell lung cancer (ALK plus NSCLC).
    Takiguchi, Yuichi
    Hida, Toyoaki
    Nokihara, Hiroshi
    Kondo, Masashi
    Kim, Young Hak
    Azuma, Koichi
    Seto, Takashi
    Nishio, Makoto
    Yoshioka, Hiroshige
    Imamura, Fumio
    Hotta, Katsuyuki
    Watanabe, Satoshi
    Goto, Koichi
    Nakagawa, Kazuhiko
    Mitsudomi, Tetsuya
    Yamamoto, Nobuyuki
    Kuriki, Hiroshi
    Inagaki, Naohito
    Tanaka, Tomohiro
    Tamura, Tomohide
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [26] Genomic heterogeneity of ALK rearrangements and acquired resistance pathways in ALK plus Advanced non-small cell lung cancer (NSCLC) treated with upfront alectinib: Preliminary results of GALILEO project
    Vita, E.
    Monaca, F.
    Russo, J.
    Stefani, A.
    Zhang, Q.
    Di Salvatore, M.
    Trisolini, R.
    Lococo, F.
    Cancellieri, A.
    Tortora, G.
    Bria, E.
    ANNALS OF ONCOLOGY, 2023, 34
  • [27] Crizotinib to overcome alectinib-resistance in non-small cell lung cancer (NSCLC) harboring EML4-ALK.
    Isozaki, Hideko
    Ichihara, Eiki
    Takigawa, Nagio
    Sendo, Toshiaki
    Tanimoto, Mitsune
    Kiura, Katsuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [28] Clinical Outcomes, Long-Term Survival and Toleration With Sequential Therapy of First-Line Crizotinib Followed by Alectinib in ALK plus NSCLC
    Zou, Z.
    Xing, P.
    Hao, X.
    Zhang, C.
    Ma, K.
    Shan, L.
    Song, X.
    Li, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1091 - S1092
  • [29] Economic evaluation crizotinib, alectinib and brigatinib in anaplastic lymphoma kinase positive (ALK plus ) non-small cell lung cancer (NSCLC).
    Choi, Briana
    Alkhatib, Nimer S.
    Pae, Elizabeth
    Babiker, Hani M.
    Garland, Linda L.
    Henglefelt, Alyssa
    McBride, Ali
    Abraham, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [30] Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK plus NSCLC): Primary results from the J-ALEX study.
    Nokihara, Hiroshi
    Hida, Toyoaki
    Kondo, Masashi
    Kim, Young Hak
    Azuma, Koichi
    Seto, Takashi
    Takiguchi, Yuichi
    Jo, Makoto Nish
    Yoshioka, Hiroshige
    Imamura, Fumio
    Hotta, Katsuyuki
    Watanabe, Satoshi
    Goto, Koichi
    Nakagawa, Kazuhiko
    Mitsudomi, Tetsuya
    Yamamoto, Nobuyuki
    Kuriki, Hiroshi
    Asabe, Ryoichi
    Tanaka, Tomohiro
    Tamura, Tomohide
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345